|Publication number||US3561444 A|
|Publication date||Feb 9, 1971|
|Filing date||May 22, 1968|
|Priority date||May 22, 1968|
|Publication number||US 3561444 A, US 3561444A, US-A-3561444, US3561444 A, US3561444A|
|Inventors||Raymond Marcel Gut Eoucher|
|Original Assignee||Bio Logics Inc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (9), Referenced by (245), Classifications (17)|
|External Links: USPTO, USPTO Assignment, Espacenet|
g nebulizer for forming and emitting the same into g a receptacle with a base ning chamber. a truncated f the receptacle so that its rger base, the smaller base being being open, a dome containing an mn and an outer, vertically g the inner, vertically disposed,
the receptacle above the trunertically disposed, column and column both being open at the y disposed, column having jacent the top thereof, a transducer mounted in the base of the receptacle, gas flow regulating means in the top of the inner, vertically disposed, column, means for excitin ucer at an ultrasonic rate such th the medicated solution in the Raymond Marcel Gut Boucher 807.544 l/l959 Great Britain................ Metuchen, N J. Primary Examiner-Richard A. Gaudet APPl- 968 Assistant Examiner-J. B Mitchell Patented 21:5 is. Attorney-Lynn G. Foster Bio-Logics, Inc. Salt Lake City, Utah acorporation of Delaware ABSTRACT: An ultrasonic dru Continuation-in-part of application Ser. No. droplets from a medicated solution 510,537, Nov. 30, 1965, now abandoned. the surrounding atmosphere havin and walls to form a liquid contai conical cup for containing the medicated solution removabl mounted in the upper portion Q 15 Claims, 23 Drawing 8 smaller base is below its la u.s. 128/194, closed and the larger base 128/24 inner, vertically disposed, colu 1m. A6lh 1/00, disposed clumnrsurrundin A61 m 15/00 column removably mounted to 128/194, cated conical cup, the inner, v 24.05,I72,l73,l86,l93,419,421,424; theouteriveflicallydisposedy 3 10/ lnquired); 324/51; 128/24 (A), (Ultrasonic bottoms Fhemfi h vemca" Nob Digest), 194 an opening therein ad References Cited UNITEDSTATESPATENTS zthelransd at a geyser IS formed from United States Patent  Inventor l l  Filed  Assignee e- .ehos uwn t tq mm mk t i m mmdw wmmm mm aflem d am m emm g yru nooa ea .mhn lrmi e wmmm foe f mwmn mmm m f mmflof uu om l m f tOmne m m w em me wmammm m m m wmm d 6 1% v uo n mS 0 wp ow me mt nmfi ww hwhn m i t i mflm u mmm 2 mflmu mhunm fi tl om woc o mm mm a Wmwmwmmm a. 7 t
, 4 1 m m f e a, /////////,/////,m hhhkmormmw \tttt \%-/o- Z ivli .J m m a w m i144a!!!"all:5115;551:1415!u 7m\ m 4 LR k a a 3mm 3 K m x l. a H 08 M 41 mm r uu nn J as h 6 E 3 3 3 1. t /=\\\t mm k n. e I 6 3 u u u n m MT m m m. M m m u" "E n H mm mm mmm m 1P ou 6 W MC W 883 m v mmm m O fr. .lW l UE 8C6 ZFGWSD ZUGG l8467 79 45666 556 99999 999 1111] ll] 226 2 94 ll 11 75624 652 47346 962 5 .2 73750 263 66386 650 1 22333 11 'PATENIED FEB 9 |97| 5 4 sum 2 or 7 \NVENTOR I RAYMOND M.G.BOUCHER PATENTEU FEB 9197! 3 551 44 SHEET 3 0F 7 l 4 INVENTO? 7 RAYMOND MG BOUCHEF? HTTOR uzvs PATENTEB FEB 9 :97:
SHEET 0F 7 lNVENTOR I 11.5. B$AYMOND HG. BoucHaR HTTORN S PATENTEI] FEB 9 I97! SHEET 5 BF 7v IA 1% f n 1 ll! Ill- I rll 4: .m
' 736 TO SIGNAL.
GENERRTOR 132 INVENTOR RAYMOND N. G. BOUCHER av GTTOR EYS PATENTEU rm 9:97: 3 551 4 SHEET 6 0F 7 INVENTOR RAYMOND M. G BOUCHER T5 an.
I M W RTTOP EYS PATENTEUFEB 9l97| 3.561.-
- sum 7 or 7 INVENTOI? Ql-WMQND M. G. BoucHER RTTORN ULTRASONIC DRUG NEBULIZER This is a continuation-in-part of my application, Ser. No. 510,537, filed Nov. 30, 1965, now abandoned.
This invention relates to ultrasonic nebulizers and more particularly to devices for producing fine liquid aerosols, as for medicinal use, through the disintegration of the liquid geyser produced by radiation pressure effect of ultrasonic vibrations of a flat ceramic crystal transducer at a relatively high frequency. In particular, the invention is directed to such devices heel holding may be used to deliver either a steady supply of medicated solution or a pulsed supply thereof.
The creation of ultrafine droplets by means of ultrasonic energy is not new. Devices to accomplish this have been constructed but in most instances the objective lay outside the area of medicinal nebulization and have depended on surface wave disintegration at a relatively low frequency. The problems associated with the development of an ultrasonic nebulizer specifically for medicinal nebulization include the production of uniformly small particles, preferably with a high percentage less than microns in diameter and of the order of 80 to 90 percent, by weight, less than microns. The nebulizer should have a reliable particle formation rate (for example, 0.l to L5 cc. per minute), and electrical requirements at reasonable voltage and power levels.
Most of the prior art drug nebulizers, which have been used to dispense nebulized medicated solutions into the atmosphere surrounding the patient or directly into the respiratory tract of the patient through a face mask or device, have been of the mechanical type wherein it was not possible to control the size of the nebulized droplets without using screens or obstacles in the aerosol path.
There is no universal agreement on the exact meaning the terms: aerosol, fog and However, there has been a recommendation that e.g., word aerosol" be limited to airborne made up of particles less than 1 micron in diameter (Conference on Aerosols, Nov. 1959, Denver, Col.). For one could say that the word fog" is used for droplets the 5 to 050 microns range and the word mist" is used for droplets in the 50 to 500 microns range. The word micromist" is often used to describe liquid dispersoids in the 5 to 25 microns range. The definitions set forth above may be used, in the specification, to describe the various dispersoids of the medicated solution.
The drug nebulizer of the the invention, utilizes high frequency ultrasonic energy to disperse fine liquid particles of the medicated solution into a It comprises a small plastic cup which contains the medicated solution and a polarized, piezoelectric ceramic (crystal) transducer which beams the ultrasonic energy to the medicated solution through the bottom of the cup. A liquid such as distilled or tap water, which is used to couple the ultrasonic energy between the ceramic transducer and the cup which contains the medicated solution, also serves as a cooling liquid to prevent the transducer from overheating and becoming ineffective.
When the is energized at the proper frequency, say, between 500 kHz. and 2 ml-lz., mechanical vibrations are set up in the coupling liquid. These mechanical vibrations occur at the frequency of the excitation signal. The mechanical vibrations are coupled through the coupling liquid to the bottom of the cup and thence to the medicated solution contained in the cup. The internal turbulence in the medicated solution is so great that the surface tension of the liquid and the cohesive forces at the gas-liquid interface are overcome and a geyser is produced due to the disintegration of the liquid into a fine mist or aerosol.
The aerosol produced at the surface of the heel-holding solution is carried out of the drug nebulizer to the atmosphere surrounding the patient or directly into the patient's respiratory tract by the gas flow produced by a small blower or by the pressure difference caused by the patient's respiration.
Drug nebulizers are intended and used for the purpose of carrying finely atomized therapeutic solutions through the lungs in order to depositthe therapeutic agent at selective sites in the pulmonary tree. This makes it possible to reach the blood circulatory system without physical infraction. For a number of years, aerosol therapy has been recognized as having many curative advantages. However, its use has been limited by the disadvantages inherent in mechanical nebulizers. There are drastic physical limitations on the size of the droplets which may be produced by mechanical means such as high-speed jets, centrifugation, impingement, etc. In order to generate aerosol and fog particles of the size required for maximum deposition of the drug in the lungs (0.4 to 10 microns), it was necessary to develop sophisticated, complex, mechanical nebulizing devices. Simple mechanical generators could not be used satisfactorily because they always produced a certain amount of drops which were too large or the drug reconcentrated through filtration or the refluxing of the large particles.
Another object is to provide a richer, more abundant nebula without the waste of the compressed-air-driven nebulizer which is noisy and often entrains noxious oil vapors. The aerosol produced by the generator is very uniform, providing optimum particle size for deposition in the lung. The nebula can be generated continuously, stored and made available to the patient only during inspiration.
Still another object is to provide a system by which the crystal transmits its sonic energy through a liquid medium to the medicament which is held in a removable cup. Liquids placed in direct contact with the crystal would penetrate into the crystal and react chemically with it causing depolarization and resultant crystal failure. Accordingly, the crystal is sealed with a suitable covering, as an epoxy resin or a thin gold layer. The liquid medium, medicament or transfer liquid aids in dissipating heat generated in the crystal.
Yet another object is to provide compression mounting for the piezoelectric crystal transducer. The mounting of the crystal provides proper support to the electrodes, seals the crystal from the coolant fluid, and eliminates damping of the sonic output.
A further object is to provide the apparatus with a replaceable cup for the material to be nebulized so that various materials can be used without great difficulty.
It is a further object of the invention to provide such a device wherein the droplet size is controlled so that the large bulk of the droplets of the drug delivered to the patient's respiratory tract are of the proper size.
It is a still further object of the invention to provide such a device wherein the output of the device is maintained at a steady rate.
It is a still further object of the invention to provide such a device wherein the output of the device is pulsed at a respiratory or similar rate.
It is a still further object of the invention to provide a source of aerosols which may be used for therapeutic or other purposes.
One feature of this invention is the provision of a nebulizing apparatus including a base, a ceramic crystal having conductive electrodes, compression clamping means holding the crystal against the base, and a seal, sealing the joint between the crystal and base.
Another feature is the provision of a removable medication cup mounted upon the base so that the ultrasonic energy is transmitted to the medicament thereby producing fine liquid aerosols through the disintegration of a liquid geyser due to the radiation pressure force field.
More particularly, the mounting for the crystal which has upper and lower conductive electrodes comprises compression clamping means holding the crystal against a base and holding a circular seal so as to close off the joint between the base and crystal, the clamping means also holding a lead between a circular washer and the lower metallized electrode. The epoxy or thin gold layer may be used to protect the upper crystal surface.
These and other objects, advantages, features and uses will be apparent during the course of the following description, when taken in conjunction with the accompanying drawings, wherein:
FIG. 1 is a plot showing the percentage of particles deposited in the respiratory tracts;
FIG. 2 is a vertical sectional view of an embodiment of ultrasonic drug nebulizer embodying the invention;
FIG. 3 is an enlarged is section of the transducer mounting used in the ultrasonic drug nebulizer of FIG. 2;
FIG. 4 is an enlarged detail of the transducer mounting of FIG. 3;
FIG. 5 is an illustration of the ultrasonic nebulizer system of the invention utilizing the embodiment of FIGS. 2-4;
FIG. 6 is a view, in perspective, of another form of ultrasonic drug nebulizer of the invention;
FIG. 7 is a front elevational view of the ultrasonic drug nebulizer of FIG. 6;
FIG. 8 is a horizontal, plan view of the ultrasonic drug nebulizer of FIG. 6;
FIG. 9 is an enlarged, sectional view, taken along the lines 9-9 of FIG. 8, viewed in the direction of the arrows;
FIG. 10 is an enlarged view similar to and of a portion of FIG. 9 showing the transducer and its mounting;
diameter through the pulmonary tree is by inertial impingement in the tracheobronchial portion. Droplets in the submicron range reach the pulmonary tree in the alveolar region mainly by diffusion under the influence of Brownian motion.
In addition to the droplet size, one must also consider the mass of the droplets when attempting to deposit a drug is inside the pulmonary tree. This is quite obvious when one considers that, since the volume varies as the cube of the diameter, one drop l0 microns in diameter will contain as much of the therapeutic agent as I000 droplets, each of which is 1 micron in diameter. Since one wishes to arrive at a size range which will deliver the maximum therapeutic benefit with the mt most readily usable droplet size, it is desirable to be able to tailor the droplet size delivered to the patient in the ideal range. This range appears to be from about 0.4 to about 10 microns in diameter.
The following table, based on I milliliter of liquid, taken in conjunction with FIG. 1, will serve to illustrate the advantage of ultrasonic nebulizers over mechanical nebulizers for the production of therapeutic aerosols.
Overall retention in respiratory tract (percent) Brownian movement in 1 second (microns) Sedimentation rate in still air in 1 second (microns) (square centimeters) N ore-Particles are of density 1 and are assumed to be spherical.
FIG. 11 is a top, horizontal, plan view, viewed in the direction of the arrows l l-l 1 of FIG. 9;
FIG. 12 is a bottom, horizontal, plan view, viewed in the direction of the arrows 12-12 of FIG. 9;
FIG. 13 is a sectional view, taken along the lines 13-13 of FIG. 11, viewed in the direction of the arrows;
FIG. 14 is'an enlarged, top, plan view of the check valve used in the ultrasonic drug nebulizer of FIG. 6;
FIG. 15 is a sectional view, taken along the lines 15-15 of FIG. 14, viewed in the direction of the arrows;
FIG. 16 is a top, plan view of the liquid containing chamber, viewed in the direction of the arrows 16-16 of FIG. 9;
FIG. 17 is a bottom, plan view of the liquid containing chamber, viewed in the direction of the arrows 17-17 of FIG.
FIG. 18 is an elevational view of the liquid containing chamber, viewed in the direction of the arrow 18 of FIG. 16;
FIG. 19 is a bottom, plan view of the truncated, conical cup, viewed in the direction of the arrows 19-19 of FIG. 9;
FIG. 20 is an enlarged, sectional view, taken on the lines 20-20 of FIG. 19, viewed in the direction of the arrows;
FIG. 21 is an enlarged, vertical sectional view, similar to that of FIG. 13, of a further embodiment of the invention;
FIG. 22 is a view, similar to that of FIG. 21 of a modification thereof; and
FIG. 23 is a schematic diagram of the circuit of the generator used with the ultrasonic drug nebulizers of FIGS. 2 and 6.
FIG. 1 is a plot showing the percent of retention of droplets in the respiratory tract against droplet size. Curve 100 illustrates the overall droplet retention in the respiratory tract against droplet size. The outline of area 102 designates the plot of percent of retention of droplets in the alveolar portion of the pulmonary tree against droplet size. The outline of area 104 designates the plot of percent of retention of droplets in the tracheobronchial portion of the pulmonary tree against droplet size and the outline of area 106 is the plot of percent of retention of droplets in the nasopharyngeal portion of the pulmonary tree against droplet size.
From FIG. 1, it can be seen that the predominant mechanism for collecting droplets larger than 1 micron in The average droplet size of a therapeutic aerosol and fog is given as the mass median diameter (MMD) which is defined as the droplet size such that one-half the mass of the aerosol is in droplets smaller in size than said droplet size. The mass median diameter is related to the mean particle diameter as shown by the following formula: log D log MMD 6.9 log a; where D mean particle diameter; MMD mass median diameter; o'= standard deviation FIG. 1 shows that a droplet size of 10 microns is collected in the tracheobronchial and nasopharyngeal regions and the overall retention in the respiratory tract (from the table) is 89 percent. A droplet, which is 0.4 micron in diameter, would be collected in the alveolar and tracheoabronchial regions and the overall retention in the respiratory tract is about 30 percent.
Thus, it can be seen that the ideal droplet size for therapeutic use is in the aerosol and fog range from 0.4 micron to 10 microns in diameter. Since these size droplets cannot be produced readily by mechanical means, other means must be found.
While illustrative embodiments of the invention are shown in the drawings and will be described in detail herein, the invention is susceptible of embodiment in many different forms and it should be understood that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the invention to the embodiment illustrated. The scope of the invention will be pointed out in the appended claims.
Referring not to FIG. 2, the nebulizing unit 10 consists of a flat-surfaced piezoelectric crystal 11 housed in an aluminum transducer base 12 and an aerosol chamber 13 mounted upon the base. The crystal 11 transmits its acoustic energy through a cooling (coupling) liquid 14 to the medicament 15 which is held in a removable cup 16 thereby creating a turbulent fountain 17. Nebulization occurs around the outer surface of the fountain producing a mist which is held in the aerosol chamber 13. This mist can be withdrawn from the chamber through an outlet 18 as needed. The radiation pressure fountain or geyser occurs only at relatively high sonic frequencies as of the order of at least 500 kilocycles and may be generated with presently available transducers operating at freouencies up to the order of 2 megacycles. The details of the crystal and mounting will be described below.
The transducer base 12 is cylindrical with cooling fins 20 on its lower portion and a shoulder 21 along its top. A fluid cavity 22 is formed within the base 12 and has a transverse lower wall 22a with an opening 22b therethrough. A plastic medication cup 16 fits into the open top of the fluid cavity 22 with its outer portion resting on the shoulder 21. The cup is tapered, having a truncated conical form with the bottom portion 23 approximately the same diameter as the face of crystal 11. The cup may be of a suitable material as a plastic, a metal foil'or the like.
A cooling (coupling) liquid 14 such as water or oil is contained within a fluid cavity 22 between the cup and the base 12. This liquid transmits the acoustic energy from the crystal 11 to the medicament which is held in the cup thereby causing a radiation pressure fountain l7 and nebulization as will be described in detail later.
Referring now to FIGS. 3 and 4, the transducer mounting is shown in detail. The piezoelectric ceramic crystal body 30 may be made of materials such as lead zirconate, lead titanate zirconate, or calcium titanate with or without traces of salts of yttrium, lanthanum, strontium, or cobalt. The'flat ceramic crystal can have various configurations, as circular, rectangular, square, etc. In one specific embodiment of the invention, the crystal is a circular flat disc with a diameter of 0.75 inch, a thickness of 0.l inch, and a nominal resonant frequency of approximately 750 kilocycles, To establish good electrical contact with the crystal body, the upper 31 and lower 32 faces are coated with electrically conductive layers, 33 and 34, respectively, of metal such as gold, platinum, irridium or silver.
The crystal ll closes opening 22b at the bottom of cavity 22 and is mounted under compression in the transducer base 12 by means of a series of clamp screws 35 which squeeze a circular shaped metal clamp ring 36 against a neoprene or synthetic rubber O-ring seal 37. Clamp ring 36 has an L-spaed cross section defining a generally rectangular space with the undersurface of wall 22a and the periphery of the crystal. Sealing ring 37 engages four surfaces.
The electrical connection to the upper face 31 of the crystal is achieved by direct contact of the base 12 with the upper metallized surface 33. A tin or copper ground lug 38 is provided on one of the clamp screws 35 to permit the base to be grounded.
The electrical connection to the lower face 32 of the crystal is achieved by direct contact of a copper foil lead 39 compressed between a circular neoprene washer 40 and the metalcoated bottom face 34 by an extending leg 36a of the metal clamp 36.
The upper face 31 of the crystal is in contact either with a liquid 14 (water, oil, etc.) or with the solution to be dispersed. Where liquid 14 is used, it serves the dual function of cooling the crystal and coupling sonic energy to the material to be dispersed. To protect the metallized surface 33 from corrosion, chemical reaction with the liquid or mechanical projections in the liquid phase during irradiation, it is covered with a sealing coating as a layer of epoxy resin 41. This design permits a satisfactory electrical contact along the circular edge 33a of the upper crystal surface and at the same time gives maximum protection to the upper vibrating face.
The sealing coating for the upper surface of the crystal must accommodate deflection of the crystal and the high accelerations which occur. For the crystal described above, driven with a voltage of the order of 150 volts (RMS), there will be a deflection of the order of 0.25 micron and accelerations as high as 500,000 G. Furthermore, the material must have good adhesive qualities, permit the dissipation of heat from the crystal and transfer the sonic energy with little attenuation. A suitable material is an epoxy resin sold under the trademark E. POX. E. by The Woodhill Chemical Corp., Cleveland, Ohio. A layer with a thickness on the order of 0.015 inch on the crystal discussed provides adequate protection without excessive heating or attenuation of the sonic energy.
In the present mounting the lower face of the ceramic crystal vibrates freely into air space 42 thus allowing near'perfect reflection of the acoustic energy in the upward direction. More than percent of the acoustic energy is contained inside the solid cone angle 45 on the axis 46 of the transducer. The solid cone angle 45 is equal to 2 sin- .61 x/R where x is the wave length of the emission and R the radius of the vibrating disc. From experimental results the maximum value of angle 45 is 12.
As shown in FIG. 2, the acoustic energy is transmitted through the cooling liquid 14 to the medicament 15 held in the cup 16 thereby creating a turbulent fountain 17. The high degree of internal turbulence achieved inside the fountain produced by the upward radiation pressure of the crystal causes nebulization to occur around the outer surface of the fountain 17.
A wide variation in the liquid level does not affect the fog production since the ceramic crystal has an excellent electroacoustic output sufiicient to disintegrate the liquid geyser regardless of liquid level. A focusing (curved) transducer is not used since it would not produce a geyser as stable as the one erected by the flat transducer.
Aerosol chamber 13 is fitted on transducer base 12, above the medication cup. Chamber 13 is a clear plastic canopy to contain the nebula generated by the device. The chamber 13 has an outlet 18 that permits the aerosol to be directly inhaled or to which accessory devices such as mouth pieces and face masks can be attached.
The air inlet 50 to the chamber is through the top 51 by means of a plastic tube 52 that extends downward to the fountain 17 produced in the medicament 15. This tube not only provides a means of allowing air to be drawn into the chamber but also contains the fountain 17 so that it does not splash up into the upper surfaces of the aerosol chamber. The larger particles impinge on the tube wall and drain back into the body of medicament 15, leaving only the smaller particles suspended. The tube also brings the inlet air into the bottom of the chamber at a velocity sufficient to push the nebula upward allowing complete utilization of the generated aerosol. The velocity of the air in the outer chamber is much lower and the larger, more dense particles fall back into the cup. A one-way valve 53 in the top of the tube allows air to enter during inhalation but then closes so that it is impossible to exhale through the chamber. In the absence of air flow, the nebula remains in the chamber and provides for an on demand delivery to the user. All of the nebula formed is drawn out by the user or falls back into the cup, resulting in complete utilization of the medicament.
FIG. 5 shows the nebulizer system which consists of a generator 60, nebulizer l0, and mask 61. The generator 60 contains an oscillator circuit which provides power which is transmitted to the transducer by a coaxial cable 62. The cable 62 is connected between an output terminal 63 at one end and copper foil lead 39 and ground lug 38 at the other end. The generator may have an on-off switch 64 and indicator light 65. Furthermore, a vemier tuning control 66 is provided for balancing the system to various medicaments. A timer 67 is provided to control the amount of time the system operates for different dosages.
To operate the nebulizer, the transducer base is filled with cold tap water to the proper level. The medication cup is then placed into the transducer base and medication is added to the cup. The plastic aerosol chamber is placed on the shoulders of the base. After throwing the On-off switch to the on" position and allowing a short period for the generator to wann up, the timer" is set to the prescribed interval. Using the vernier tuning control, the system is tuned for the desired amount of nebulization activity.
A mask 51 or other means may be placed on the nebulizer outlet 18 of the mist chamber, and the patient may breathe the aerosol medicament.
In FIGS. 6 through 21, there are shown a further embodiment of ultrasonic drug nebulizer of the invention and some modifications thereof.
Nebulizer 110 is seen to cm comprise (FIGS. 68), cabinet 112, receptacle housing 114, transparent dome 116 and air pipe 118. The electronic signal generator is contained in cabinet 112, is actuated by timer switch 120 and is tuned by means of tuning control 122. Pilot light 124 is used to indicate that power has been applied to the signal generator and to indicate safe connection to the power mains as will appear further on in this description.
FIG. 9 is an enlarged sectional view of the receptacle and transparent done used in the ultrasonic drug nebulizer 110. Receptacle 114 is preferably formed of a metal such as aluminum and is finned as shown in FIGS. 16 and 17 to facilitate the transfer to heat from the receptacle to the surrounding atmosphere. Receptacle 126 is provided on cabinet 112 to receive receptacle 114.
When receptacle 114 is placed on receptacle 126, connector 128 on the receptacle 114 mates with connector 130 which is mounted in cabinet 112 and thereby makes electrical connection between the output of the signal generator and transducer 134 which is mounted in the base of receptacle 1 14. In a preferred form of the invention, the insertion of receptacle 114 on receptacle 126 also closes limit switch 136, as shown in FIG. 9. This serves as a safety feature and prevents the user from turning the generator on with its output unloaded.
Alternatively, switch 136 can be omitted or locked closed so that receptacle 114 may be removed from the cabinet and connection made between connectors 128 and 130 by means of a suitable jumper cable (not shown). shown). In such circumstances, the receptacle and dome assembly may be held by the patient at a distance (depending upon the jumper length) from the cabinet. However, since it is necessary that the dome 116 be held in a vertical attitude, it is not advisable to have weak patients use the nebulizer in this manner.
Receptacle 114 is filled with water 138 or a similar liquid to a suitable level such that the vibrations of transducer 134 are coupled to medicated solution 140. Medicated solution 140 is contained in truncated conical cup 142 which is preferably formed of a transparent polycarbonate resin such as is marketed under the trademark LEXAN by the General Electric Co. Truncated conical cup 142 is provided with a circumferential lip 144 surrounding its open, larger base to facilitate its installation in receptacle 114. Lip 144 rests on the top of receptacle 114 and the truncated conical cup 142 is held in place by dome 116 which is threaded to receptacle 114 as shown at 146.
Dome 116 is formed of a transparent material, preferably a polycarbonate resin such as LEXAN,'and comprises inner, vertically disposed, column 148 and outer, vertically disposed, column 150 surrounding column 148. The aerosol is emitted to the surrounding atmosphere through exit 152 which is connected to column 150.
Transducer 134 is formed of flat circular disc 154 to which suitable electrodes 156 have been applied in a manner well known in the transducer art FIG. Disc 154 is preferably formed of a polarized, piezoelectric ceramic such as barium titanate, lead titanate, barium-lead titanate or any other suitable material with or additives. Transducer 134, upon excitation at a frequency in the range from about 450 kHz. to about 2 mHz., vibrates in its thickness mode and transmits mechanical vibrations to coupling liquid 138. The vibrations are transmitted, in turn, to medicated solution 140 and are of sufficient intensity to form geyser 158 therefrom.
Receptacle 114 is provided with opening 160 in the bottom thereof which is threaded as shown at 161 and with lip 162 overlying the threaded opening. O-ring 164 surrounds transducer 134 to keep it in position against lip 162 and to prevent any liquid leak around the transducer and its mounting. The upper electrode 154 is in intimate contact with lip 162 and thereby makes electrical contact with receptacle 114 (equipment ground).
Cup 166 is formed of a metal such as brass with its open base facing the lower electrode 156 and is held in position against the electrode by means of insulating ring 168 which threads into threads 161. Ring 168 serves to insulate cup 166 from receptacle 114. The circumference of the open base of cup 166 is in intimate, electrical contact with the lower electrode 156 of transducer 134. Spring 170 makes the electrical connection between cup 166 and the hot lead of connector 128.
A gas, such as air, is introduced at a pressure above ambient pressure into column 148 through pipe 118 which is connected to an air blower in cabinet 112. The air blower is of a type well known in the art and the structural details are not shown. The gas enters column 148 and impinges against geyser 158 and causes the mist droplets to enter column 150 and to be emitted through exit 152 as the gas sweeps past geyser 158 and up into column 150.
Since different ailments require different droplet sizes for ideal therapeutic benefit, the gas flow past geyser 158 can be modulated to select the desired droplet size to be emitted through exit 152. The blower is run at constant velocity and the airflow is controlled by means of valve assembly 174. Valve assembly 174 comprises rotating control 176 and flaptype, check valve 178.
Check valve 178 (FIGS. 14 and 15) is normally a part of dome 116 and is in the gas stream input to column 148. It comprises an outer support 180 to which spider 182 is attached. Membrane 184 of material such as neoprene is fixed to the center of spider 182 with its periphery free. It is biased upward so that it is normally closed. When the membrane is pushed down by gas pressure or otherwise. the valve opens and the gas enters the column. This membrane is principally useful when the nebulizer is used without the blower. However, for the sake of simplicity of manufacture, the same valve assembly is used when the nebulizer is operated both with and without the blower.
Rotating control 176 is a part of pipe 118 and is provided with openings 186 which cooperate with openings 188 in fixed element 177 to control the gas flow. When the openings are aligned as shown in FIG. 13, the maximum flow of gas is delivered to the column 148. To ensure that check valve 178 is open when used with the blower, control 176 is provided with a pair of stiff wires 190. These wires 190 open the valve mechanically when pipe 118 is connected to dome 116.
The embodiment illustrated is provided with three control positions, as shown by indicia 192 of FIG. 9. By way of example, in the maximum position, the gas flow from a blower running at 3,250 r.p.m. is 12 1i./min. which will produce an aerosol with the droplets having a mass median diameter between l'kto 3 microns. At the same blower velocity in the middle position a gas flow of 6 1i./min. is obtained and produces a light fog with the droplets having a mass median diameter between 3 and 6 microns. At the same blower velocity, the minimum position delivers a gas flow of 3 1i./min. and a fog in which the mass median diameter of the droplets is between 7 and 10 microns. The foregoing is by way of example and is not intended to limit the scope of the invention.
FIGS. 16 through 18 are enlarged views of receptacle 114. It is preferably formed of aluminum or some other electrically and thermally conductive material. The outer periphery is provided with fins 194 to accelerate the transmission of heat away from the receptacle. Threads 196 at the top are used to connect dome 116 to receptacle 114. Screws 197 are utilized to hold the transducer assembly in place at the bottom of receptacle 114.
FIGS. 19 and 20 are views of the truncated conical cup 142 which is preferably formed of polycarbonate resin such as LEXAN. This material is transparent so that the action in the interior may be observed and is stable at sterilization temperatures so that it may be treated in an autoclave without harm or damage. Its large base 198 is open and its small base 200 is closed so that, in use, its small base is down. To facilitate the maximum transfer of acoustical energy from the transducer through the coupling liquid to the medicated solution in the cup, it is desirable to make base 200 as thin as possible. Generally, the thickness of base 200 should be about onequarter of that of the wall 202. By way of example but not by way of limitation of the scope of the invention, a wall thickness of 0.02 inch and a base thickness of 0.005 inch have produced excellent results.
In FIG. 23, there is shown the schematic diagram of signal generator 132. It delivers a power output of approximately 30 watts at a nominal frequency of 800 kHz. It comprises tuned grid electron coupled oscillator 204 which feeds power amplifier 206. The output of power amplifier 206 is delivered to connector 130. Tuning control 122 is adjustable by the operator and is used to adjust the geyser to maximum height.
Since ultrasonic drug nebulizers of the invention are intended to be used by persons who are not technically trained in the electronic and electroacoustical arts, it has been found advisable to utilize pilot light 124 as a warning light to indicate correct or incorrect connection to the AC mains.
The generator is provided with a standard, three-prong, 1 15 volt AC connector. When it is properly connected to the AC mains, pilot light 124 remains out when either interlock switch 136, or timer switch 120, or both are open. It goes on when both switches are closed.
However, if the ground connection is not made to the AC mains or if the hot terminal 208 is connected to the grounded terminal of the AC mains, pilot light 124 will light when either or both switches 120 and 136 are open. The light will go out when both switches are closed. This gives an immediate indication to the patient or technician that the connection should be corrected and will prevent possible electric shocks.
Operation of the ultrasonic drug nebulizer 110 proceeds as follows: the receptacle 114 is filled with water to the marked level and the cup 142 is placed on top of the receptacle 114. Medicated solution is now added to the cup to the desired level. Dome 116 is screwed in place on receptacle 114 thereby locking cup 142 in position. The assembly is now placed in position in receptacle 126 so that connection is made between connectors 128 and 130 and-limit switch 136 is closed. Next, pipe 118 is connected to dome 116 and the nebulizer is ready for operation. The timer is turned to the desired time, which turns on the generator and blower, and the geyser after 15 seconds forms in the medicated solution. The tuning control is adjusted to produce maximum geyser height and is left there. The valve control is set for the desired droplet size and therapeutic treatment commences and continues until the set time expires and the generator and blower turn off.
FIG. 21 is an enlarged sectional view of an alternative form of valve which may be used with the ultrasonic nebulizer of FIG. 6. Pipe 118 is disconnected from dome 116 and flaptype, check valve 210, which is similar to check valve 178, is inserted at the top of column 148. A respiratory mask such as mask 61 of FIG. 5 is suitably connected to exit 152. Then, air is drawn into column 148 when the patient inhales and valve 210 is closed when the patient stops inhaling or exhales.
FIG. 22 is a view similar to F IG. 13 showing another form of valve used with the ultrasonic nebulizer of HG. 6. Valve assembly 212 is similar to valve assembly 174 and is in the forced gas stream between pipe 118 and column 148. It is provided with rotating control 214 and fixed element 216. Element 216 is provided with openings 220 and rotating control 214 is provided with openings 218. The construction of flap valve 210 is the same as that of valve 178 and the amount of gas (air) received by column 148 is controlled by the position of rotating control 214 and the relationship of the positions of openings 218 with the positions of openings 220. Check valve 210 is constructed so that it opens under the pressure of the gas delivered by blower 172 and closes when there is insufficient pressure. This prevents the gas from escaping from column 148 back into pipe 118.
Ultrasonic drug nebulizers of the invention may be used for all types of treatment as well as for aerosol studies in flame spectroscopy and similar scientific investigations. ln addition, a pulsed valve may be substituted for the valve illustrated and described to produce apulsed output emission instead of the constant output delivered by the device described heretofore. 75
The output of the device may be emitted in a room. in a tent or through the typical respirator mask directly to the respiratory tract of the patient.
The invention is not limited to the particular arrangements of the apparatus described, but may be variously modified without departing from the spirit and scope of the invention.
1. An ultrasonic drug nebulizer for forming a mist from a medicated solution and emitting the same into the surrounding atmosphere comprising:
a receptacle having a base with a sealed opening therein and walls to form a liquid containing chamber;
a truncated conical cup for containing the medicated solution in isolated relation to any source of solution, the cup being removably mounted to the walls intermediate the length thereof substantially in sealed relation so that the base of the receptacle is below the base of the cup, the base of the cup being closed;
a dome containing an inner, vertically disposed, unobstructed influent column and an outer, vertically disposed, effluent column surrounding the inner column, the dome being removably mounted to the receptacle above the truncated conical cup, the sealed opening, the base of the cup and the inner column being in vertical alignment;
the inner column and the outer column both being fully open at the bpttom thereof, the outer column having an effluent opening therein adjacent the top thereof;
gas flow regulating means in the top of the inner column;
a transducer mounted at the base of the receptacle so as to cover the opening in sealed relation;
means for exciting the transducer at an ultrasonic rate such at that a geyser is formed from the medicated solution in the truncated conical cup, said means for exciting being arranged such that, the geyser extends upward in alignment with the inner influent column; and means for introducing gas at a pressure above ambient pressure into the inner column through the gas flow regulating means in the top thereof to impinge directly on the geyser and thereby force the mist of the geyser into the outer column to be discharged through the effluent opening therein. 2. The invention of claim 1 wherein the dome is formed of transparent material such as a polycarbonate resin which is stable at sterilization temperatures and through which the geyser formed from the medicated solution may be observed.
3. The invention of claim 2 wherein the truncated conical cup is formed of a material such as a polycarbonate resin which is stable at sterilization temperatures.
4. The invention of claim 3 wherein the base of the truncated conical cup is thinner than the walls thereof so that maximum ultrasonic energy is transmitted from the transducer through the liquid to the medicated solution.
5. The invention of claim 4 wherein: the gas flow regulating means is a valve; and the means for introducing gas into the inner column comprises: a blower; and a pipe connecting the blower to the top of the inner column such that the valve is open when the pipe is connected thereto and is closed when the pipe is disconnected therefrom. 6. The invention of claim 5 wherein the valve comprises an opening, the size of which may be varied to thereby control the flow rate of the gas entering the inner column to thereby control the size of the liquid droplets which are emitted from the outer column.
7. The invention of claim 6 wherein the means for exciting the transducer at an ultrasonic rate comprises:
an electronic signal generator having a transformer with a primary and a secondary;
the primary being connected to a source of three wire, AC voltage and the secondary being connected to a rectifier power supply;
a switch connected in series with the primary; and
a pilot light connected from one side of the primary to ground such that if the connection to the source of AC voltage is improper, the pilot light is lit with the switch open and is extinguished with the switch closed.
8. The invention of claim 7 wherein the transducer comprises:
a polarized ceramic disc having an upper electrode and a lower electrode on the opposite faces thereof;
a cylindrical brass cup having a closed bottom and a wall;
a threaded opening in the base of the liquid chamber larger than the diameter of the brass cup and of the polarized ceramic disc;
a lip in the base of the liquid chamber overlying the threaded opening;
an insulating ring surrounding the brass cup and having external threads engaging the threaded opening to electrically insulate the brass cup from the liquid chamber;
the polarized ceramic disc being mounted above the brass cup so that its lower electrode makes contact with the brass cup and its upper electrode makes contact with the lip in the base of the liquid chamber;
an insulated O-ring surrounding the polarized ceramic disc to inhibit the flow of liquid out of the liquid chamber; and
means for making electrical connection to the brass cup and to the liquid chamber.
9. The invention of claim I wherein the truncated conical cup is formed of a material such as a polycarbonate resin which is stable at sterilization temperatures.
10. The invention of claim 9 wherein the base of the truncated conical cup is thinner than the walls thereof so that maximum ultrasonic energy is transmitted from the transducer through the liquid to the medicated solution.
11. The invention of claim 1 wherein:
the gas flow regulating means is a valve; and
the means and introducing gas into the inner, vertically disposed, column comprises:
a pipe connecting the blower to the top of the inner, vertically disposed, column such that the valve is open when the pipe is connected thereto and is closed when the pipe is disconnected therefrom. 12. The invention of claim 11 wherein the opening in the valve may be varied to thereby control the flow rate of the gas entering the inner, vertically disposed, column.
13. The invention of claim 1 wherein the means for exciting the transducer at an ultrasonic rate comprises:
an electronic signal generator having a transformer with a primary and a secondary;
the primary being connected to a source of three wire, AC voltage and the secondary being connected to a rectifier power supply;
a switch connected in series with the primary; and
a pilot light connected from one side of the primary to ground such that if the connection to the source of AC voltage is improper, the pilot light is lit with the switch open and is extinguished with the switch closed.
14. The invention of claim 1 wherein the outer surfaces of the walls of the receptacle are timed to facilitate the transfer of heat therefrom.
15. In an ultrasonic drug nebulizer having a liquid chamber in which a driving transducer is mounted adjacent an opening in the base of the liquid chamber, the improvement comprismg:
a polarized ceramic disc having an upper electrode and a lower electrode on the opposite faces thereof;
a cylindrical brass cup having a closed bottom and a wall;
a threaded opening in the base of the liquid chamber larger in size than the diameter of the brass cup and of the polarized ceramic disc;
a lip in the base of the liquid chamber overlying the threaded opening;
an insulating ring surrounding the brass cup and having external threads engaging the threaded opening to electrically insulate the brass cu from the liquid chamber; the polarized ceramic disc eing mounted above the brass cup, the upper electrode making contact with the lip in the base of the liquid chamber; an insulated O-ring surrounding the polarized ceramic disc to inhibit the flow of liquid out of the liquid chamber; and means for making electrical connection to the brass cup and to the liquid chamber.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2267547 *||Mar 18, 1940||Dec 23, 1941||Zimmerman Charles E||Facial machine|
|US2863075 *||Dec 15, 1953||Dec 2, 1958||Fry Francis J||Ultrasonic transducer|
|US3137836 *||Aug 25, 1955||Jun 16, 1964||Glover Clyde P||Support for electro-acoustic transducer|
|US3285242 *||Jul 1, 1963||Nov 15, 1966||American Cystoscope Makers Inc||Surgical headlight and light source|
|US3360664 *||Oct 30, 1964||Dec 26, 1967||Gen Dynamics Corp||Electromechanical apparatus|
|DE962296C *||Aug 16, 1941||Apr 18, 1957||Siemens Ag||Piezoelektrischer Schwingungserzeuger, insbesondere zur Beschallung eines Gutes|
|DE1056065B *||Mar 5, 1955||Apr 23, 1959||Siemens Ag||Einrichtung zum Zerstaeuben von Fluessigkeiten|
|DE1103522B *||Oct 24, 1957||Mar 30, 1961||Transform Roentgen Matern Veb||Abatmungseinrichtung fuer mittels Ultraschall erzeugte Aerosole|
|GB807544A *||Title not available|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3690317 *||Oct 29, 1970||Sep 12, 1972||Bendix Corp||Sonic nebulizer|
|US3774602 *||Jan 3, 1972||Nov 27, 1973||American Hospital Supply Corp||Ultrasonic nebulizer for inhalation therapy|
|US3812854 *||Oct 20, 1972||May 28, 1974||R Buckles||Ultrasonic nebulizer|
|US3864440 *||Aug 2, 1973||Feb 4, 1975||Respiratory Care||Humidifier and heater for delivered gas|
|US4031171 *||Dec 23, 1975||Jun 21, 1977||Mikuni Kogyo Kabushiki Kaisha||Ultrasonic air humidifying apparatus|
|US4087495 *||Mar 23, 1977||May 2, 1978||Mikuni Kogyo Kabushiki Kaisha||Ultrasonic air humidifying apparatus|
|US4094317 *||Jun 11, 1976||Jun 13, 1978||Wasnich Richard D||Nebulization system|
|US4113809 *||Apr 4, 1977||Sep 12, 1978||Champion Spark Plug Company||Hand held ultrasonic nebulizer|
|US4738806 *||Jul 30, 1986||Apr 19, 1988||Sanyo Electric Co., Ltd.||Humidifier for refrigeration showcase|
|US4776990 *||Sep 14, 1987||Oct 11, 1988||Rhinotherm Netzer Sereni||Method and apparatus for nebulizing a liquid|
|US4877989 *||Jan 12, 1989||Oct 31, 1989||Siemens Aktiengesellschaft||Ultrasonic pocket atomizer|
|US4911866 *||Nov 25, 1988||Mar 27, 1990||The Walt Disney Company||Fog producing apparatus|
|US5063922 *||Oct 27, 1988||Nov 12, 1991||Etala-Hameen Keuhkovammayhdistys R.Y.||Ultrasonic atomizer|
|US5139016 *||Dec 29, 1989||Aug 18, 1992||Sorin Biomedica S.P.A.||Process and device for aerosol generation for pulmonary ventilation scintigraphy|
|US5158716 *||Mar 30, 1989||Oct 27, 1992||Sanko Electric Machine Manufacturer Co. Ltd.||Atomizer for hairdressing|
|US5170782 *||Sep 12, 1991||Dec 15, 1992||Devilbiss Health Care, Inc.||Medicament nebulizer with improved aerosol chamber|
|US5171215 *||Aug 22, 1991||Dec 15, 1992||Flanagan Dennis F||Endermic method and apparatus|
|US5209225 *||Nov 19, 1991||May 11, 1993||Glenn Joseph G||Flow through nebulizer|
|US5429302 *||May 19, 1993||Jul 4, 1995||Fisons Corporation||Nebulizing element and device|
|US5485828 *||Apr 28, 1993||Jan 23, 1996||Hauser; Jean-Luc||Portable device for micropulverization generated by ultrasound waves|
|US5643868 *||Jun 6, 1995||Jul 1, 1997||Autoimmune, Inc.||Method of treating or preventing type 1 diabetes by oral administration of insulin|
|US5716002 *||Jun 29, 1995||Feb 10, 1998||Siemens Aktiengesellschaft||Ultrasonic atomizer|
|US5720955 *||Jun 7, 1995||Feb 24, 1998||Autoimmune, Inc.||Method of treating rheumatoid arthritis with soluble collagen|
|US5843886 *||Jun 2, 1995||Dec 1, 1998||Autoimmune, Inc.||Method of treating or preventing Type 1 diabetes by oral administration of insulin|
|US5856446 *||Jul 5, 1996||Jan 5, 1999||Autoimmune Inc.||Method of treating rheumatoid arthritis with low dose type II collagen|
|US5858968 *||Jun 2, 1995||Jan 12, 1999||Autoimmune Inc.||Method of treating or preventing type 1 diabetes by oral administration of insulin|
|US6283118 *||Oct 13, 1999||Sep 4, 2001||Hsueh-Yu Lu||Ultrasonic nebulizer|
|US6478754||Apr 23, 2001||Nov 12, 2002||Advanced Medical Applications, Inc.||Ultrasonic method and device for wound treatment|
|US6533803||Dec 22, 2000||Mar 18, 2003||Advanced Medical Applications, Inc.||Wound treatment method and device with combination of ultrasound and laser energy|
|US6559188||Sep 15, 2000||May 6, 2003||Novartis Ag||Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes|
|US6569099||Jan 12, 2001||May 27, 2003||Eilaz Babaev||Ultrasonic method and device for wound treatment|
|US6601581 *||Nov 1, 2000||Aug 5, 2003||Advanced Medical Applications, Inc.||Method and device for ultrasound drug delivery|
|US6601777 *||Jan 30, 2001||Aug 5, 2003||Msp Corporation||Suspended particle container for an atomizer|
|US6615824 *||May 4, 2001||Sep 9, 2003||Aerogen, Inc.||Apparatus and methods for the delivery of medicaments to the respiratory system|
|US6623444||Mar 21, 2001||Sep 23, 2003||Advanced Medical Applications, Inc.||Ultrasonic catheter drug delivery method and device|
|US6663554||Aug 7, 2002||Dec 16, 2003||Advanced Medical Applications, Inc.||Ultrasonic method and device for wound treatment|
|US6703361||Dec 2, 1998||Mar 9, 2004||Autoimmune Inc.||Method of treating or preventing Type 1 diabetes by oral administration of insulin|
|US6705312 *||Aug 22, 2002||Mar 16, 2004||Omron Corporation||Inhalator attachment and nebulizer equipped with same|
|US6726186||Aug 10, 2001||Apr 27, 2004||Sonia Gaaloul||Apparatus for cleaning and refreshing fabrics with an improved ultrasonic nebulizer|
|US6761729||Feb 14, 2003||Jul 13, 2004||Advanced Medicalapplications, Inc.||Wound treatment method and device with combination of ultrasound and laser energy|
|US6812205||Mar 15, 2001||Nov 2, 2004||The Brigham & Women's Hospital, Inc.||Suppression of vascular disorders by mucosal administration of heat shock protein peptides|
|US6854661 *||Dec 18, 2002||Feb 15, 2005||Multi Media Electronics, Inc.||Misting fogger|
|US6854718 *||Jan 30, 2003||Feb 15, 2005||Hwang Sun Enterprise Co., Ltd.||Vaporizer|
|US6878749||Jan 16, 2003||Apr 12, 2005||Novartis Ag||Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes|
|US6927223||May 25, 2001||Aug 9, 2005||Washington State University Research Foundation||Use of serotonin agents for adjunct therapy in the treatment of cancer|
|US6960173||Jan 30, 2001||Nov 1, 2005||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US6964647||Oct 6, 2000||Nov 15, 2005||Ellaz Babaev||Nozzle for ultrasound wound treatment|
|US6968840||Jan 15, 2003||Nov 29, 2005||Aerogen, Inc.||Methods and systems for operating an aerosol generator|
|US6978941||Apr 9, 2004||Dec 27, 2005||Aerogen, Inc.||Base isolated nebulizing device and methods|
|US7021560 *||Sep 25, 2003||Apr 4, 2006||Deka Products Limited Partnership||System and method for aerosol delivery|
|US7032590||Jan 5, 2004||Apr 25, 2006||Aerogen, Inc.||Fluid filled ampoules and methods for their use in aerosolizers|
|US7040549||Mar 21, 2003||May 9, 2006||Aerogen, Inc.||Systems and methods for controlling fluid feed to an aerosol generator|
|US7066398||Mar 30, 2001||Jun 27, 2006||Aerogen, Inc.||Aperture plate and methods for its construction and use|
|US7104463||Oct 6, 2005||Sep 12, 2006||Aerogen, Inc.||Base isolated nebulizing device and methods|
|US7164008||Nov 17, 2003||Jan 16, 2007||University Of Iowa Research Foundation||Isolated complexes of endotoxin and MD-2|
|US7174888||Sep 5, 2003||Feb 13, 2007||Aerogen, Inc.||Liquid dispensing apparatus and methods|
|US7195011||Jun 30, 2004||Mar 27, 2007||Aerogen, Inc.||Convertible fluid feed system with comformable reservoir and methods|
|US7201167||Mar 14, 2005||Apr 10, 2007||Aerogen, Inc.||Method and composition for the treatment of lung surfactant deficiency or dysfunction|
|US7219880 *||Apr 26, 2005||May 22, 2007||Chuan-Pan Huang||Safety protection device and control circuit for instantaneous atomization device|
|US7267121||Sep 30, 2004||Sep 11, 2007||Aerogen, Inc.||Aerosol delivery apparatus and method for pressure-assisted breathing systems|
|US7278419 *||Jan 30, 2004||Oct 9, 2007||Novo Nordisk A/S||Method for treating diabetes mellitus in a patient|
|US7290541||Jun 30, 2004||Nov 6, 2007||Aerogen, Inc.||Aerosol delivery apparatus and method for pressure-assisted breathing systems|
|US7322349||Jun 18, 2003||Jan 29, 2008||Aerogen, Inc.||Apparatus and methods for the delivery of medicaments to the respiratory system|
|US7331339||Nov 23, 2004||Feb 19, 2008||Aerogen, Inc.||Methods and systems for operating an aerosol generator|
|US7360536||Jan 7, 2003||Apr 22, 2008||Aerogen, Inc.||Devices and methods for nebulizing fluids for inhalation|
|US7413729||Jan 13, 2006||Aug 19, 2008||University Of Iowa Research Foundation||Sialic acid permease system|
|US7431704||Jun 7, 2006||Oct 7, 2008||Bacoustics, Llc||Apparatus and method for the treatment of tissue with ultrasound energy by direct contact|
|US7448375||May 17, 2005||Nov 11, 2008||Aradigm Corporation||Method of treating diabetes mellitus in a patient|
|US7469700||Jun 25, 2003||Dec 30, 2008||Trudell Medical Limited||Nebulizing catheter system for delivering an aerosol to a patient|
|US7472705 *||Jun 25, 2003||Jan 6, 2009||Trudell Medical Limited||Methods of forming a nebulizing catheter|
|US7504379||May 13, 2005||Mar 17, 2009||Cornell Research Foundation, Inc.||Protection of cardiac myocardium|
|US7600511 *||Oct 30, 2002||Oct 13, 2009||Novartis Pharma Ag||Apparatus and methods for delivery of medicament to a respiratory system|
|US7608440 *||Sep 7, 2004||Oct 27, 2009||The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland||Apparatus for ultrasonic microbial disruption|
|US7608681||Dec 22, 2000||Oct 27, 2009||Genentech, Inc.||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|US7628339||May 5, 2006||Dec 8, 2009||Novartis Pharma Ag||Systems and methods for controlling fluid feed to an aerosol generator|
|US7635749||Sep 26, 2006||Dec 22, 2009||Genentech, Inc.||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|US7655420||Dec 19, 2007||Feb 2, 2010||Celltech R & D, Inc.||Methods to increase or decrease bone density|
|US7677467||Apr 20, 2005||Mar 16, 2010||Novartis Pharma Ag||Methods and devices for aerosolizing medicament|
|US7677915 *||Dec 28, 2004||Mar 16, 2010||Areva T&D Sa||Electrical contact element for medium or high voltage electrical equipment, and corresponding, method and equipment|
|US7686285||Mar 23, 2005||Mar 30, 2010||Barnstead Thermolyne Corporation||Environmental chamber and ultrasonic nebulizer assembly therefor|
|US7713218||Jun 27, 2005||May 11, 2010||Celleration, Inc.||Removable applicator nozzle for ultrasound wound therapy device|
|US7748377||Oct 30, 2007||Jul 6, 2010||Novartis Ag||Methods and systems for operating an aerosol generator|
|US7753285||Jul 13, 2007||Jul 13, 2010||Bacoustics, Llc||Echoing ultrasound atomization and/or mixing system|
|US7767150 *||Aug 5, 2004||Aug 3, 2010||Solomon Zaromb||Aerosol collection apparatus and methods|
|US7771642||Apr 1, 2005||Aug 10, 2010||Novartis Ag||Methods of making an apparatus for providing aerosol for medical treatment|
|US7779831 *||Apr 19, 2007||Aug 24, 2010||Ric Investments, Llc||Ultrasonic nebulizer with metal coated ultrasonic generator|
|US7780095||Jul 13, 2007||Aug 24, 2010||Bacoustics, Llc||Ultrasound pumping apparatus|
|US7785277||Jun 23, 2006||Aug 31, 2010||Celleration, Inc.||Removable applicator nozzle for ultrasound wound therapy device|
|US7785278||Sep 18, 2007||Aug 31, 2010||Bacoustics, Llc||Apparatus and methods for debridement with ultrasound energy|
|US7878991||Aug 31, 2007||Feb 1, 2011||Bacoustics, Llc||Portable ultrasound device for the treatment of wounds|
|US7896539||Aug 16, 2005||Mar 1, 2011||Bacoustics, Llc||Ultrasound apparatus and methods for mixing liquids and coating stents|
|US7909033||May 3, 2007||Mar 22, 2011||Comedica Incorporated||Breathing treatment apparatus|
|US7914470||Apr 1, 2004||Mar 29, 2011||Celleration, Inc.||Ultrasonic method and device for wound treatment|
|US7914517||Nov 1, 2004||Mar 29, 2011||Trudell Medical International||System and method for manipulating a catheter for delivering a substance to a body cavity|
|US7934703 *||Mar 9, 2006||May 3, 2011||Akira Tomono||Mist generator and mist emission rendering apparatus|
|US7946291||Apr 20, 2004||May 24, 2011||Novartis Ag||Ventilation systems and methods employing aerosol generators|
|US7954486||Apr 1, 2005||Jun 7, 2011||The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services||Aerosol delivery systems and methods|
|US7959859 *||Jan 18, 2007||Jun 14, 2011||Sparks David W||Ultrasonic sanitation device and associated methods|
|US7971588||Mar 24, 2005||Jul 5, 2011||Novartis Ag||Methods and systems for operating an aerosol generator|
|US8051854||Sep 14, 2007||Nov 8, 2011||Comedica Incorporated||Continuous high-frequency oscillation breathing treatment apparatus|
|US8062588||Mar 22, 2006||Nov 22, 2011||Zimek Technologies Ip, Llc||Ultrasonic sanitation device and associated methods|
|US8088396||Aug 29, 2008||Jan 3, 2012||University Of Iowa Research Foundation||Isolated complexes of endotoxin and modified MD-2|
|US8137682||Sep 20, 2007||Mar 20, 2012||University Of Iowa Research Foundation||Isolated complexes of covalently cross-linked endotoxin and modified MD-2|
|US8196573||Jan 23, 2008||Jun 12, 2012||Novartis Ag||Methods and systems for operating an aerosol generator|
|US8227441||Feb 2, 2010||Jul 24, 2012||Celltech R & D, Inc.||Methods to increase or decrease bone density|
|US8235919||Apr 7, 2003||Aug 7, 2012||Celleration, Inc.||Ultrasonic method and device for wound treatment|
|US8336545||Jan 16, 2007||Dec 25, 2012||Novartis Pharma Ag||Methods and systems for operating an aerosol generator|
|US8348177||Jun 15, 2009||Jan 8, 2013||Davicon Corporation||Liquid dispensing apparatus using a passive liquid metering method|
|US8353287 *||Apr 19, 2007||Jan 15, 2013||Ric Investments, Llc||Disposable drug solution cup for an ultrasonic nebulizer|
|US8398001||Jun 19, 2006||Mar 19, 2013||Novartis Ag||Aperture plate and methods for its construction and use|
|US8491521||Jul 17, 2008||Jul 23, 2013||Celleration, Inc.||Removable multi-channel applicator nozzle|
|US8539944||Apr 8, 2008||Sep 24, 2013||Novartis Ag||Devices and methods for nebulizing fluids for inhalation|
|US8544462||Apr 27, 2007||Oct 1, 2013||The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention||Systems and methods for aerosol delivery of agents|
|US8561604||Feb 12, 2007||Oct 22, 2013||Novartis Ag||Liquid dispensing apparatus and methods|
|US8562547||Apr 1, 2008||Oct 22, 2013||Eliaz Babaev||Method for debriding wounds|
|US8609029||Jun 3, 2010||Dec 17, 2013||Zimek Technologies Ip, Llc||Ultrasonic sanitation and disinfecting device and associated methods|
|US8616195||Apr 27, 2004||Dec 31, 2013||Novartis Ag||Nebuliser for the production of aerosolized medication|
|US8656908||May 2, 2011||Feb 25, 2014||The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention||Aerosol delivery systems and methods|
|US8687191||Dec 9, 2010||Apr 1, 2014||Deka Products Limited Partnership||Detection system and method for aerosol delivery|
|US8691772||Jan 4, 2006||Apr 8, 2014||Yeda Research And Development Co. Ltd.||HSP60, HSP60 peptides and T cell vaccines for immunomodulation|
|US8980951||Jan 21, 2014||Mar 17, 2015||Kansas State University Research Foundation||Sesquiterpenes for antifungal applications|
|US9050434||May 15, 2008||Jun 9, 2015||Comedica Incorporated||Lung therapy device|
|US9101949||Dec 13, 2006||Aug 11, 2015||Eilaz Babaev||Ultrasonic atomization and/or seperation system|
|US9108211||Apr 17, 2006||Aug 18, 2015||Nektar Therapeutics||Vibration systems and methods|
|US9151425||Oct 21, 2010||Oct 6, 2015||Comedica Incorporated||Multiple conduit connector apparatus and method|
|US20010013554 *||Mar 30, 2001||Aug 16, 2001||Scott Borland||Aperture plate and methods for its construction and use|
|US20020103448 *||Jan 30, 2001||Aug 1, 2002||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US20030062038 *||Aug 22, 2002||Apr 3, 2003||Omron Corporation||Inhalator attachment and nebulizer equipped with same|
|US20030114367 *||Sep 30, 1999||Jun 19, 2003||Yehuda Shoenfeld||Composition for the prevention and/or treatment of artherosclerosis|
|US20030140921 *||Jan 15, 2003||Jul 31, 2003||Aerogen, Inc.||Methods and systems for operating an aerosol generator|
|US20030150445 *||Oct 30, 2002||Aug 14, 2003||Aerogen, Inc.||Apparatus and methods for delivery of medicament to a respiratory system|
|US20030162816 *||Jan 16, 2003||Aug 28, 2003||Gatlin Marjorie Regan||Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes|
|US20030226633 *||Jun 4, 2003||Dec 11, 2003||Fujitsu Limited||Method and apparatus for fabricating bonded substrate|
|US20030236560 *||Apr 7, 2003||Dec 25, 2003||Eilaz Babaev||Ultrasonic method and device for wound treatment|
|US20040001827 *||Jun 28, 2002||Jan 1, 2004||Dennis Mark S.||Serum albumin binding peptides for tumor targeting|
|US20040004133 *||Mar 21, 2003||Jan 8, 2004||Aerogen, Inc.||Systems and methods for controlling fluid feed to an aerosol generator|
|US20040035490 *||Jun 18, 2003||Feb 26, 2004||Aerogen, Inc.||Apparatus and methods for the delivery of medicaments to the respiratory system|
|US20040084049 *||Jun 25, 2003||May 6, 2004||Trudell Medical Limited||Nebulizing catheter system and methods of use and manufacture|
|US20040084050 *||Jun 25, 2003||May 6, 2004||Trudell Medical Limited.||Nebulizing catheter system and methods of use and manufacture|
|US20040124258 *||Dec 18, 2002||Jul 1, 2004||Monitto Perry H.||Misting fogger|
|US20040182383 *||Jan 30, 2004||Sep 23, 2004||Igor Gonda||Method for treating diabetes mellitus in a patient|
|US20040186384 *||Apr 1, 2004||Sep 23, 2004||Eilaz Babaev||Ultrasonic method and device for wound treatment|
|US20040188534 *||Apr 9, 2004||Sep 30, 2004||Aerogen, Inc.||Base isolated nebulizing device and methods|
|US20040253247 *||Dec 22, 2000||Dec 16, 2004||Dennis Mark S||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|US20040256488 *||Jun 30, 2004||Dec 23, 2004||Aerogen, Inc.||Convertible fluid feed system with comformable reservoir and methods|
|US20050011514 *||Apr 27, 2004||Jan 20, 2005||Aerogen, Inc.||Nebuliser for the production of aerosolized medication|
|US20050053612 *||Aug 17, 2004||Mar 10, 2005||Granstein Richard D.||Nucleotide regulation of immune responses|
|US20050067511 *||Sep 25, 2003||Mar 31, 2005||Deka Products Limited Partnership||System and method for aerosol delivery|
|US20050085556 *||Sep 3, 2004||Apr 21, 2005||Paul Wentworth||Detection of cholesterol ozonation products|
|US20050085557 *||Sep 3, 2004||Apr 21, 2005||Paul Wentworth||Therapeutic procedures|
|US20050106179 *||Nov 17, 2003||May 19, 2005||Weiss Jerrold P.||Isolated complexes of endotoxin and MD-2|
|US20050124663 *||Jan 14, 2005||Jun 9, 2005||Gatlin Marjorie R.||Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes|
|US20050172954 *||Nov 23, 2004||Aug 11, 2005||Aerogen Inc.||Methods and systems for operating an aerosol generator|
|US20050178847 *||Apr 1, 2005||Aug 18, 2005||Aerogen, Inc.||Methods of making an apparatus for providing aerosol for medical treatment|
|US20050197283 *||Apr 15, 2005||Sep 8, 2005||Vascular Biogenics Ltd.||Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease|
|US20050199236 *||Apr 20, 2005||Sep 15, 2005||Aerogen, Inc.||Methods and devices for aerosolizing medicament|
|US20050205089 *||Jan 19, 2005||Sep 22, 2005||Aerogen, Inc.||Methods and devices for aerosolizing medicament|
|US20050209141 *||Oct 13, 2004||Sep 22, 2005||Silver Randi B||Mast cell-derived renin|
|US20050217666 *||Mar 24, 2005||Oct 6, 2005||Aerogen, Inc.||Methods and systems for operating an aerosol generator|
|US20050229926 *||Mar 14, 2005||Oct 20, 2005||Aerogen, Inc.||Method and composition for the treatment of lung surfactant deficiency or dysfunction|
|US20050229928 *||Jun 30, 2004||Oct 20, 2005||Aerogen, Inc.||Aerosol delivery apparatus and method for pressure-assisted breathing systems|
|US20050274377 *||May 17, 2005||Dec 15, 2005||Igor Gonda||Method of treating diabetes mellitus in a patient|
|US20050287153 *||Apr 13, 2005||Dec 29, 2005||Genentech, Inc.||Serum albumin binding peptides for tumor targeting|
|US20060019891 *||May 13, 2005||Jan 26, 2006||Jay Edelberg||Protection of cardiac myocardium|
|US20060025716 *||Aug 18, 2005||Feb 2, 2006||Eilaz Babaev||Nozzle for ultrasound wound treatment|
|US20060058710 *||Sep 22, 2005||Mar 16, 2006||Eilaz Babaev||Ultrasound wound treatment method and device using standing waves|
|US20060073152 *||Sep 22, 2005||Apr 6, 2006||Genentech, Inc.||Therapeutic agents with decreased toxicity|
|US20060194740 *||Feb 23, 2006||Aug 31, 2006||Ulevitch Richard J||NOD1 as an anti-tumor agent|
|US20060210554 *||Mar 6, 2006||Sep 21, 2006||Paul Wentworth||Detection of cholesterol ozonation products|
|US20060213508 *||Mar 23, 2005||Sep 28, 2006||Barnstead/Thermolyne Corporation||Environmental chamber and ultrasonic nebulizer assembly therefor|
|US20060217359 *||Mar 6, 2006||Sep 28, 2006||Paul Wentworth||Therapeutic procedures|
|US20060227612 *||Jun 7, 2006||Oct 12, 2006||Ebrahim Abedifard||Common wordline flash array architecture|
|US20060228364 *||Mar 2, 2006||Oct 12, 2006||Genentech, Inc.||Serum albumin binding peptides for tumor targeting|
|US20060252141 *||Sep 7, 2004||Nov 9, 2006||Coakley William T||Apparatus for ultrasonic microbial disruption|
|US20070016110 *||Jun 27, 2005||Jan 18, 2007||Eilaz Babaev||Removable applicator nozzle for ultrasound wound therapy device|
|US20070023547 *||Jun 19, 2006||Feb 1, 2007||Aerogen, Inc.||Aperture plate and methods for its construction and use|
|US20070031611 *||Aug 4, 2005||Feb 8, 2007||Babaev Eilaz P||Ultrasound medical stent coating method and device|
|US20070044792 *||Aug 30, 2005||Mar 1, 2007||Aerogen, Inc.||Aerosol generators with enhanced corrosion resistance|
|US20070051307 *||Aug 16, 2005||Mar 8, 2007||Babaev Eilaz P||Ultrasound apparatus and methods for mixing liquids and coating stents|
|US20070059769 *||Sep 5, 2006||Mar 15, 2007||Ola Blixt||High throughput glycan microarrays|
|US20070088245 *||Jun 23, 2006||Apr 19, 2007||Celleration, Inc.||Removable applicator nozzle for ultrasound wound therapy device|
|US20070111590 *||Dec 28, 2004||May 17, 2007||Areva T&D Sa||Electrical contact element for medium or high voltage electrical equipment, and corresponding, and corresponding method and equipment|
|US20070267010 *||Jan 16, 2007||Nov 22, 2007||Fink James B||Methods and systems for operating an aerosol generator|
|US20070275928 *||Jul 23, 2007||Nov 29, 2007||Gatlin Marjorie R|
|US20080017198 *||Aug 6, 2007||Jan 24, 2008||Aerogen, Inc.||Aerosol delivery apparatus and method for pressure-assisted breathing systems|
|US20080019968 *||May 18, 2007||Jan 24, 2008||The Scripps Reasearch Institute||Detection, prevention and treatment of breast cancer|
|US20080032918 *||Jan 24, 2007||Feb 7, 2008||Cornell Research Foundation, Inc.||Mast cell-derived renin|
|US20080051693 *||Aug 31, 2007||Feb 28, 2008||Bacoustics Llc||Portable Ultrasound Device for the Treatment of Wounds|
|US20080054091 *||Dec 13, 2006||Mar 6, 2008||Bacoustics Llc||Ultrasonic atomization and/or seperation system|
|US20080060644 *||Oct 5, 2007||Mar 13, 2008||Novo Nordisk A/S - Novo Alle||Method Of Treating Diabetes Mellitus In A Patient|
|US20080066754 *||Sep 14, 2007||Mar 20, 2008||Faram Joseph D||Continuous high-frequency oscillation breathing treatment apparatus|
|US20080125365 *||Sep 20, 2007||May 29, 2008||University Of Iowa Research Foundation||Isolated complexes of covalently cross-linked endotoxin and modified md-2|
|US20080142002 *||Jan 23, 2008||Jun 19, 2008||Aerogen, Inc.||Methods and Systems for Operating an Aerosol Generator|
|US20080142616 *||Dec 15, 2006||Jun 19, 2008||Bacoustics Llc||Method of Producing a Directed Spray|
|US20080149096 *||Dec 21, 2007||Jun 26, 2008||Aerogen, Inc.||Apparatus and Methods for the Delivery of Medicaments to the Respiratory System|
|US20080177221 *||Dec 21, 2007||Jul 24, 2008||Celleration, Inc.||Apparatus to prevent applicator re-use|
|US20080183109 *||Apr 1, 2008||Jul 31, 2008||Bacoustics Llc||Method for debriding wounds|
|US20080183200 *||Apr 1, 2008||Jul 31, 2008||Bacoustics Llc||Method of selective and contained ultrasound debridement|
|US20080245362 *||Sep 6, 2006||Oct 9, 2008||George Moessis||Nebuliser|
|US20080283051 *||May 15, 2008||Nov 20, 2008||Joseph Dee Faram||Lung therapy device|
|US20090024076 *||Jul 7, 2008||Jan 22, 2009||Celleration, Inc.||Nozzle for ultrasound wound treatment|
|US20090028795 *||Feb 27, 2006||Jan 29, 2009||Ulevitch Richard J||NOD1 as an Anti-Tumor Agent|
|US20090043248 *||Jul 17, 2008||Feb 12, 2009||Celleration, Inc.||Removable multi-channel applicator nozzle|
|US20090068207 *||Apr 11, 2006||Mar 12, 2009||Vascular Biogenics Ltd.||Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease|
|US20090081274 *||Sep 24, 2008||Mar 26, 2009||Cornell Research Foundation, Inc.||Mast cell-derived renin|
|US20090107503 *||Oct 22, 2008||Apr 30, 2009||Trudell Medical Limited||Nebulizing catheter system and methods of use and manufacture|
|US20090110692 *||Aug 29, 2008||Apr 30, 2009||Weiss Jerrold P||Isolated complexes of endotoxin and modified md-2|
|US20090123376 *||Sep 25, 2006||May 14, 2009||Dennis Mark S||Therapeutic agents with decreased toxicity|
|US20090177122 *||Dec 23, 2008||Jul 9, 2009||Celleration, Inc.||Methods for treating inflammatory skin disorders|
|US20090177123 *||Dec 23, 2008||Jul 9, 2009||Celleration, Inc.||Methods for treating inflammatory disorders|
|US20110079616 *||Jun 29, 2010||Apr 7, 2011||Holmes Charles R||Apparatus And Method Of Dispensing An Attractant Or Scent Blocker|
|US20130112197 *||Apr 26, 2011||May 9, 2013||Pari Pharma Gmbh||Operating method for an aerosol delivery device and aerosol delivery device|
|US20140084495 *||Sep 20, 2013||Mar 27, 2014||Great Innovations, LLC||Convertible humidifier|
|DE4036244A1 *||Nov 14, 1990||May 21, 1992||Heyer Gmbh Carl||Temp.-controlled aerosol generating device - with holder for removable container carrier|
|EP0014989A1 *||Feb 19, 1980||Sep 3, 1980||C.H. Boehringer Sohn||Inhalation device|
|EP0098924A2 *||Apr 8, 1983||Jan 25, 1984||Bröcker Ladenbau GmbH & Co. KG||Device for the atomization of liquids|
|EP0689879A1 *||Jun 27, 1995||Jan 3, 1996||Siemens Aktiengesellschaft||Ultrasonic atomizer|
|EP1182292A1 *||Aug 16, 2000||Feb 27, 2002||THE PROCTER & GAMBLE COMPANY||Apparatus for cleaning and refreshing fabrics with an improved ultrasonic nebulizer, and improved ultrasonic nebulizer|
|EP1190729A1 *||Sep 22, 2000||Mar 27, 2002||Industrial Technology Research Institute||Ultrasonic nebulizer|
|EP1509259A2 *||May 20, 2003||Mar 2, 2005||AeroGen, Inc.||Apparatus for providing aerosol for medical treatment and methods|
|EP1757311A2||Dec 22, 2000||Feb 28, 2007||Genentech, Inc.||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|EP1757701A1||Dec 22, 2000||Feb 28, 2007||Genentech, Inc.||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|EP1927597A1||Aug 18, 2005||Jun 4, 2008||Novabiotics Limited||Antibacterial peptides|
|EP2011489A2||Jul 9, 2003||Jan 7, 2009||Roberta Gottlieb||Method to inhibit ischemia and reperfusion injury|
|EP2011507A2||Sep 15, 2000||Jan 7, 2009||Novartis AG||Pharmaceutical composition of nateglinide and another antidiabetic agent|
|EP2096118A1||Aug 18, 2005||Sep 2, 2009||Novabiotics Limited||Antifungal peptides|
|EP2180054A1||Dec 22, 2000||Apr 28, 2010||Genentech, Inc.||Methods and compositions for prolonging elimination half-times of bioactive compounds|
|EP2258428A1 *||Apr 1, 2005||Dec 8, 2010||The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services||Aerosol delivery systems|
|EP2258724A1||Nov 21, 2003||Dec 8, 2010||Celltech R & D, Inc.||Modulating immune responses using multimerized anti-CD83 antibodies|
|EP2277522A2||Feb 28, 2003||Jan 26, 2011||UCB Manufacturing, Inc.||Methods for increasing or decreasing bone density and identifying molecules|
|EP2295067A1||May 23, 2001||Mar 16, 2011||The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services||E-selectin for inducing immunotolerance|
|EP2322215A2||Jul 4, 2005||May 18, 2011||Pfizer Products Inc.||Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody|
|EP2322217A2||Jul 4, 2005||May 18, 2011||Pfizer Products Inc.||Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody|
|EP2335727A2||Jul 4, 2005||Jun 22, 2011||Pfizer Products Inc.||Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody|
|WO1989006147A1 *||Oct 27, 1988||Jul 13, 1989||Etelae Haemeen Keuhkovammayhdi||Ultrasonic atomizer|
|WO1990006171A1 *||Nov 17, 1989||Jun 14, 1990||Walt Disney Prod||Fog producing apparatus|
|WO2002014594A1 *||Aug 10, 2001||Feb 21, 2002||Procter & Gamble||Apparatus for cleaning and refreshing fabrics with an improved ultrasonic nebulizer, and improved ultrasonic nebulizer|
|WO2002055131A2 *||Oct 23, 2001||Jul 18, 2002||Advanced Medical Applic Inc||Method and device for ultrasound drug delivery|
|WO2007028203A1 *||Sep 6, 2006||Mar 15, 2007||Intelligent Medical Technologi||Nebuliser|
|WO2007090247A1 *||Feb 12, 2007||Aug 16, 2007||Claudia Bonifer||Nebuliser|
|WO2008149334A2 *||Apr 29, 2008||Dec 11, 2008||Amiram Keshet||Nebulizer and driver circuity therefor particularly useful for converting liquids to fine sprays at extremely low rates|
|WO2010047829A1||Oct 23, 2009||Apr 29, 2010||The Scripps Research Institute||Mutant hepatitis c virus e2 polypeptides for hcv treatment|
|WO2011121289A2||Mar 30, 2011||Oct 6, 2011||Novabiotics Limited||Compounds and their use|
|WO2012076842A1||Dec 6, 2011||Jun 14, 2012||University Of Durham||Synthetic retinoids for control of cell differentiation|
|WO2012156724A2||May 16, 2012||Nov 22, 2012||The Technology Partnership Plc||Separable membrane improvements|
|U.S. Classification||128/200.16, 261/DIG.480, 261/1, 261/DIG.650, 601/2|
|International Classification||A61M15/00, A61M11/00, B05B17/06|
|Cooperative Classification||A61M2011/001, B05B17/0661, A61M15/0085, Y10S261/48, B05B17/0615, Y10S261/65|
|European Classification||B05B17/06B7B, A61M15/00F, B05B17/06B1|